An ophthalmic composition for administration to an eye containing 0.001-1000 micrograms per ml by weight of thymosin beta 4 (Tβ4), or an N-terminal variant, a C-Terminal variant, a conservative variant or an isoform thereof, and one or more of a tonicity agent, a buffering agent, a pH adjusting agent, and a solvent, a method of treating an eye of a human for dry eye syndrome by administering an effective amount of the ophthalmic composition to the eye of the human to treat the dry eye syndrome, and a method of treating a cornea of an eye of a human for corneal epithelial thinning by administering an effective amount of the ophthalmic composition to the cornea to treat corneal epithelial thinning.
